Trial · NCT04991753
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 | Group 1: Placebo | -0.58 | 95% Confidence Interval -1.24 to 0.07 | Score on a scale | |
| Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 | Group 2: Nipocalimab | -1.03 | 95% Confidence Interval -1.66 to -0.40 | Score on a scale | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12 | Group 1: Placebo | 20.0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12 | Group 2: Nipocalimab | 45.5 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12 | Group 1: Placebo | 5.0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12 | Group 2: Nipocalimab | 15.2 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12 | Group 1: Placebo | 0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12 | Group 2: Nipocalimab | 12.1 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12 | Group 1: Placebo | 0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12 | Group 2: Nipocalimab | 6.1 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12 | Group 1: Placebo | 10.0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12 | Group 2: Nipocalimab | 21.2 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12 | Group 1: Placebo | 10.0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12 | Group 2: Nipocalimab | 21.2 | -1.66 to -0.40 | Percentage of Participants | |
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | Group 1: Placebo | -0.21 | 95% Confidence Interval -0.45 to 0.04 | Score on a scale | |
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | Group 2: Nipocalimab | -0.42 | 95% Confidence Interval -0.66 to -0.19 | Score on a scale | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Group 1: Placebo | 60.0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Group 2: Nipocalimab | 81.8 | -1.66 to -0.40 | Percentage of Participants | |
| Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 1: Placebo | 0 | -1.24 to 0.07 | Percentage of Participants | |
| Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | Group 2: Nipocalimab | 9.1 | -1.66 to -0.40 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04991753/results